News | Cardiac Resynchronization Therapy Devices (CRT) | May 22, 2018

Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival

Real-world data on AdaptivCRT algorithm presented at Heart Rhythm 2018

Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival

May 22, 2018 — Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved patient survival. The data were presented at Heart Rhythm 2018, the Heart Rhythm Society's 39th Annual Scientific Sessions, May 9-12 in Boston.

In a real-world, prospective registry of 1,835 patients, use of the AdaptivCRT algorithm was associated with a 31 percent relative reduction in all-cause mortality compared to conventional cardiac resynchronization therapy (CRT) (p=0.02). The AdaptivCRT algorithm personalizes therapy, adjusting how the implanted CRT device paces the heart according to minute-to-minute evaluations of each patient's heart rhythm, and is being assessed for superiority over conventional CRT in a randomized clinical trial, AdaptResponse.

"Heart failure patients typically have several other medical conditions and are at risk for frequent hospitalizations and even death," said Jagmeet P. Singh, M.D., Ph.D., associate chief of the Cardiology Division of Massachusetts General Hospital in Boston. "The AdaptivCRT algorithm is not only linked to improved patient survival, but it also has previously been shown to reduce the risk of atrial fibrillation and hospital readmissions."

Atrial fibrillation (AF), an irregular quivering or rapid rhythm in the heart's upper chambers, is one of the most common heart rhythm disorders, and a large percentage of heart failure patients also have AF.1 Prior analyses of AdaptivCRT have shown a 46 percent reduction in episodes of AF lasting more than 48 hours, compared to patients treated with conventional CRT.2

Additionally, AdaptivCRT allows physicians to tailor CRT to the individual needs of each patient, which has been shown to translate into a 59 percent reduction in a patient's odds of a 30-day heart failure readmission.3 Evidence from the Adaptive CRT randomized clinical trial further demonstrated that AdaptivCRT increases CRT response rate, reduces unnecessary right ventricular pacing, and improves clinical outcomes for patients with normal AV conduction.4-7

Heart failure is a progressive condition, affecting more than 26 million people worldwide, consuming intensive resources during hospitalizations and continuing to cause problems following hospital stays, with 90-day readmission rates of 40 percent.8 CRT is an established treatment for some heart failure patients that uses an implantable defibrillator (CRT-D) or pacemaker (CRT-P) to improve the pumping efficiency of the heart.

For more information: www.medtronic.com

Related Content

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A digital screening for...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral
Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award
News | Atrial Fibrillation | December 18, 2018
Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the International...

An example of the new generation of cardiac monitoring device that is replacing Holter monitoring is the Cardea Solo wearable sensor. The FDA-cleared device automatically analyzes data when the device is turned back into the physician's office and automatically produces a draft summary report. This technology can simplify the workflow by eliminating the need for third-party involvement.

Feature | Atrial Fibrillation | September 13, 2018
Rapid advances in technology to monitor atrial fibrillation (AF or Afib) are enabling clinicians to access real-time
Atrial Fibrillation Patients Diagnosed With Carotid Atery Disease Face Increased Risk of Dementia

Image courtesy of Intermountain Medical Center Heart Institute

News | Atrial Fibrillation | May 24, 2018
Atrial fibrillation patients who are diagnosed with carotid artery disease face higher risks for developing dementia,...
Overlay Init